|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, reduced GATA2 expression suppresses the differentiation but promotes the proliferation of EVI1-expressing leukemic cells, which accelerates EVI1-driven leukemogenesis.
|
31820561 |
2020 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
|
31649131 |
2019 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings support a novel mechanism of leukemogenesis through EVI1 overexpression.
|
30315161 |
2018 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms.
|
29288910 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
|
28630119 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the mechanism of EVI1-mediated leukemogenesis has not been fully elucidated.
|
28391050 |
2017 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we identified a mechanism whereby a GATA2 distal hematopoietic enhancer (G2DHE or -77-kb enhancer) is brought into close proximity to the EVI1 gene in inv(3)(q21;q26) inversions, leading to leukemogenesis.
|
24703906 |
2014 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EVI1 gene (3q26) codes for a transcription factor with important roles in normal hematopoiesis and leukemogenesis.
|
22689058 |
2013 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As activation of Evi1 has been shown to coincide with NRAS mutations in human acute myeloid leukemia, our murine model recapitulates crucial events in human leukemogenesis.
|
22847614 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EVI1 gene (3q26) codes for a zinc finger transcription factor with important roles in both mammalian development and leukemogenesis.
|
21750091 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, mechanistic basis of Evi1-mediated leukemogenesis has not been fully elucidated.
|
21289308 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that RUNX1-EVI1 plays indispensable roles in leukemogenesis of t(3;21)-positive leukemia.
|
19016745 |
2008 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its role in leukemogenesis is still unclear but it is thought that overall EVI1 can act mostly as a transcription repressor through its interaction with a subset of histone deacetylases.
|
18655152 |
2008 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In keeping with findings in other recurrent 3q26 rearrangements, overexpression of the EVI1 gene appears to be the major contributor to leukemogenesis in patients with a t(3;17).
|
18815193 |
2008 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that EVI1 overexpression was the major factor contributing to leukemogenesis, and the late appearance of the Ph chromosome is closely associated with the progression to an aggressive form of leukemia.
|
18206536 |
2008 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
|
17575132 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EVI1 gene codes for a zinc finger transcription factor with important roles both in normal development and in leukemogenesis.
|
17507183 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is suggested that PRDM16 and MDS1/EVI1 share a common molecular mechanism for the leukemogenesis of RUNX1-associated leukemia.
|
16015645 |
2005 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The exact mechanism by which EVI1 induces leukemogenesis is not clear.
|
12972028 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.
|
11965542 |
2002 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This identifies a novel function of Evi-1 as a member of corepressor complexes and suggests that aberrant recruitment of corepressors is one of the mechanisms for Evi-1-induced leukemogenesis.
|
11313276 |
2001 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This identifies a novel function of Evi-1 as a member of corepressor complexes and suggests that aberrant recruitment of corepressors is one of the mechanisms involved in Evi-1-induced leukemogenesis.
|
11587364 |
2001 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This may be the first case among the therapy-related cases of MDS/AML reported whose karyotypes were followed and in which the mRNA expression of EVI 1 gene involved was directly proved in the leukemogenesis process of chemotherapy-induced secondary MDS and AML.
|
9861236 |
1998 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To clarify the roles of AML1/ETO(MTG8) and AML1/Evi-1 in leukemogenesis, we investigated subcellular localization of these chimeric proteins by immunofluorescence labeling and subcellular fractionation of COS-7 cells that express these chimeric proteins.
|
9473235 |
1998 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, AML1/Evi-1 may contribute to leukemogenesis by specifically blocking growth-inhibitory signaling of TGF-beta in the t(3;21) leukemia.
|
9834202 |
1998 |